ChemDiv and Berlex Announce Collaboration
News Mar 13, 2006
ChemDiv, Inc. has announced that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The partners will work on the discovery of potential new lead compounds against several selected GPCR targets.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies.
"We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc.
"ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE